Health Technology Assessment
This article was originally published in RAJ Devices
UK's NICE and CMS in US in collaboration agreement
You may also be interested in...
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.